{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/dxcm-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/dxcm-stock-analysis/data.json",
 "title": "DexCom (DXCM) Stock Forecast & Price Target (2026)",
 "description": "DexCom Inc. (DXCM) stock: Healthcare, Medical Devices. $32.6B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "DexCom Inc. (DXCM)",
 "published": "2026-07-22T09:46:40+00:00",
 "modified": "2026-09-16T09:10:55.215+00:00",
 "generated": "2026-09-16T12:49:59.342Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "DXCM",
  "name": "DexCom Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Medical Devices",
  "country": "United States",
  "website": "https://www.dexcom.com"
 },
 "quote": {
  "price": 86.45,
  "previousClose": 84.68,
  "change": 1.77,
  "changePercent": 2.09,
  "open": 84.040001,
  "high": 87.36,
  "low": 83.26,
  "volume": 5960900,
  "averageVolume": 3509950,
  "marketCap": 32622838134,
  "fiftyTwoWeekHigh": 92.59,
  "fiftyTwoWeekLow": 54.11,
  "marketOpen": false,
  "asOf": "2026-09-16T09:10:55.000Z"
 },
 "statistics": {
  "pe": 34.16996,
  "eps": 2.53,
  "dividendYield": 0,
  "beta": 1.419,
  "priceToSales": 6.5650077,
  "priceToBook": 12.446012,
  "revenueTtm": 4969200128,
  "grossMargin": 0.6343625802506878,
  "returnOnEquity": 0.38491002
 },
 "technicals": {
  "rsi": 41,
  "macd": 0.19,
  "sma50": 82.96,
  "sma200": 71.62,
  "rsiSignal": "Neutral",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 75,
  "consensus": "Buy",
  "fairValue": 86.45,
  "analystTarget": 94,
  "analystCount": 28,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-16T09:10:55.000Z",
  "priceAtAnalysis": 86.45,
  "volatility": {
   "daily": 1.87,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 84.72,
  "aggressiveEntry": 86.45,
  "stopLoss": 78.46,
  "stopLossPercent": 7.39,
  "targets": [
   88.96,
   93.19,
   97.43
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 50.4,
    "base": 95.51,
    "upside90th": 181
   },
   {
    "year": 2028,
    "downside10th": 42.74,
    "base": 105.53,
    "upside90th": 260.59
   },
   {
    "year": 2029,
    "downside10th": 38.54,
    "base": 116.6,
    "upside90th": 352.77
   },
   {
    "year": 2030,
    "downside10th": 35.88,
    "base": 128.82,
    "upside90th": 462.58
   },
   {
    "year": 2031,
    "downside10th": 34.09,
    "base": 142.33,
    "upside90th": 594.32
   },
   {
    "year": 2032,
    "downside10th": 32.86,
    "base": 157.25,
    "upside90th": 752.62
   },
   {
    "year": 2033,
    "downside10th": 32.02,
    "base": 173.74,
    "upside90th": 942.67
   },
   {
    "year": 2034,
    "downside10th": 31.48,
    "base": 191.96,
    "upside90th": 1170.52
   },
   {
    "year": 2035,
    "downside10th": 31.17,
    "base": 212.09,
    "upside90th": 1443.15
   },
   {
    "year": 2036,
    "downside10th": 31.04,
    "base": 234.33,
    "upside90th": 1768.75
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "DXCM Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$84.04",
    "Day Range": "$83.26 to $87.36",
    "Prev Close": "$84.68",
    "Volume": "5.96M",
    "52-Week Range": "$54.11 to $92.59",
    "Market Cap": "$32.62B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Valuation is broadly in line with sector peers (7% difference), suggesting fair market pricing relative to industry standards."
   ]
  },
  {
   "id": "financials",
   "title": "DXCM Financial Performance",
   "text": [
    "Analysis: In the last 5 quarters, DXCM beat estimates 5 times. The stock rose 3 times the next day. Price tends to react positively to beats."
   ]
  },
  {
   "id": "analysis",
   "title": "DXCM Analysis",
   "text": [
    "DexCom Inc. (DXCM) is currently trading above its 50-day SMA of $82.96 and its 200-day SMA of $71.62, indicating a generally positive trend. However, the price is currently below its 20-day EMA of $86.63, suggesting some near-term weakness. The RSI is at 41, which is neutral, and the MACD is slightly positive at 0.19, signaling a lack of strong momentum in either direction. Volume has been above average recently, with the latest volume at 5.96 million compared to an average of 3.51 million. Key support levels are near the 50-day SMA, while resistance may be found near recent highs. The neutral RSI and MACD suggest that the stock is not exhibiting extreme overbought or oversold conditions, positioning it for potential consolidation or a gradual move based on fundamental catalysts.",
    "DexCom Inc. (DXCM) has a history of exceeding analyst EPS estimates, most recently with a 14.75% surprise in the quarter to June 2026, indicating strong operational performance.",
    "The company is projected to achieve 10.00% revenue growth in the current quarter and 12.00% for the full year, outpacing sector averages and signaling continued market demand.",
    "A significant majority of analysts maintain Buy or Outperform ratings, with a median price target of $94.00, reflecting confidence in the company's future prospects.",
    "Insiders have sold a net $14.8 million in stock against $1 million in purchases, indicating some level of profit-taking or portfolio rebalancing by management.",
    "DexCom's price-to-sales ratio of 6.57 is substantially higher than the sector median of 3.7, suggesting the stock may be overvalued if growth falters.",
    "DexCom Inc. (DXCM) is expected to continue its growth trajectory, driven by its leading position in the continuous glucose monitoring market and ongoing technological advancements. The base case scenario anticipates the stock to potentially reach its median analyst target price of $94.00 within the next 6-12 months, representing an 8.7% upside from the current price of $86.45. Forward-looking revenue growth estimates of 10-12% for the current year and 11% for next year, coupled with strong analyst conviction, support this outlook. Potential upside catalysts include further market penetration, new product launches, and positive clinical data, which could drive the stock towards its higher analyst targets. Conversely, increased competition, regulatory challenges, or a significant shift in insider sentiment could pressure the stock, potentially leading it towards its lower support levels or even the downside projection of $35.88 from the long-range simulation."
   ],
   "lists": {
    "ProTips": [
     "Monitor insider selling activity closely; while currently moderate, a significant increase could signal waning management confidence.",
     "DexCom's premium valuation metrics, particularly its price-to-sales ratio, suggest that future growth must consistently meet or exceed expectations to justify the current stock price.",
     "Consider the competition in continuous glucose monitoring; advancements by rivals could impact DexCom's market share and pricing power."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Consistent Earnings Beats",
     "text": "DexCom Inc. (DXCM) has a history of exceeding analyst EPS estimates, most recently with a 14.75% surprise in the quarter to June 2026, indicating strong operational performance.",
     "source": "Earnings Reports"
    },
    {
     "type": "Bullish",
     "title": "Strong Revenue Growth Projections",
     "text": "The company is projected to achieve 10.00% revenue growth in the current quarter and 12.00% for the full year, outpacing sector averages and signaling continued market demand.",
     "source": "Analyst Estimates"
    },
    {
     "type": "Bullish",
     "title": "Positive Analyst Sentiment",
     "text": "A significant majority of analysts maintain Buy or Outperform ratings, with a median price target of $94.00, reflecting confidence in the company's future prospects.",
     "source": "Wall Street Summary"
    },
    {
     "type": "Bearish",
     "title": "Moderate Insider Selling",
     "text": "Insiders have sold a net $14.8 million in stock against $1 million in purchases, indicating some level of profit-taking or portfolio rebalancing by management.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Premium Valuation Metrics",
     "text": "DexCom's price-to-sales ratio of 6.57 is substantially higher than the sector median of 3.7, suggesting the stock may be overvalued if growth falters.",
     "source": "Company Fundamentals"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "DexCom Inc. (DXCM) exhibits a P/E ratio of 34.17, which is above the sector median of 31.9, but its price-to-sales ratio of 6.57 is significantly higher than the sector median of 3.7, indicating a premium valuation. The company's return on equity stands at a strong 38.49%, well above the sector average of 6.9%, and its profit margin of 20.12% and operating margin of 24.33% are strong. While the valuation appears stretched on a P/S basis, the company's superior profitability and growth metrics justify some premium. The revenue growth of 13.1% reported is above the sector average of 8.1%. The debt-to-equity ratio of 0.53 is slightly higher than the sector median, but manageable given the company's strong profitability and cash flow generation.",
    "DexCom Inc. (DXCM) has a track record of exceeding earnings expectations, most recently reporting an EPS of $0.70 for the quarter to June 2026, surpassing estimates by 14.75% and leading to an 11.95% stock price increase. Prior quarters also show consistent beats, with the quarter to March 2026 EPS coming in at $0.56 against an estimate of $0.47. This pattern of positive earnings surprises suggests strong operational execution and demand for its products.",
    "DexCom Inc. (DXCM) faces valuation risk, with its price-to-sales ratio significantly exceeding the sector median. Moderate insider selling, with total sales of $14.8 million, warrants monitoring, although the overall analyst consensus remains positive. Competition within the continuous glucose monitoring market is intensifying, posing a potential threat to market share and pricing power."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "32.62B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "34.17"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "2.53"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "92.59"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "54.11"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Neutral SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($82.96) above the 200-day SMA ($71.62), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Neutral",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "41.00"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "0.19"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "82.96"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "71.62"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.19",
    "Correlation with Nasdaq 100 (QQQ)": "+0.16",
    "Correlation with Bitcoin (BTC)": "+0.10",
    "Correlation with Gold (XAU)": "+0.04"
   }
  },
  {
   "id": "trade-plans",
   "title": "DXCM Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (41.0) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$88.96",
    "TARGET 2": "$93.19",
    "TARGET 3": "$97.43",
    "STOP LOSS": "$78.46"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+6.82%",
    "Average Feb return": "+0.89%",
    "Average Mar return": "+1.77%",
    "Average Apr return": "+0.94%",
    "Average May return": "+2.28%",
    "Average Jun return": "+6.31%",
    "Average Jul return": "+0.38%",
    "Average Aug return": "+5.09%",
    "Average Sep return": "-8.49%",
    "Average Oct return": "+0.70%",
    "Average Nov return": "+8.23%",
    "Average Dec return": "-0.58%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.87%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in DXCM in September 2016 would be worth about $37,159 today, compared with about $35,497 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in DXCM today could grow to about $27,106 by 2036 in the base case, with a bull case near $204,598 and a bear case around $3,591. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "DXCM Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $129 for DXCM by 2030 in the base case, from $86.45 today (1.5x over 4 years). The downside path ends near $35.88. These are outcomes of a Monte Carlo simulation run on DXCM's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using DXCM's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. DXCM is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "DXCM simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$50.40",
        "$95.51",
        "$181"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$42.74",
        "$106",
        "$261"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$38.54",
        "$117",
        "$353"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$35.88",
        "$129",
        "$463"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$34.09",
        "$142",
        "$594"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$32.86",
        "$157",
        "$753"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$32.02",
        "$174",
        "$943"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$31.48",
        "$192",
        "$1,171"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$31.17",
        "$212",
        "$1,443"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$31.04",
        "$234",
        "$1,769"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "ILMN Illumina Inc. NASDAQ $222.36 +6.80%",
     "url": "https://clearank.com/stock/ilmn-stock-analysis/"
    },
    {
     "text": "BMY Bristol-Myers Squibb Company NYSE $63.73 -0.58%",
     "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/"
    },
    {
     "text": "CAPR Capricor Therapeutics, Inc. NASDAQ $8.56 -2.84%",
     "url": "https://clearank.com/stock/capr-stock-analysis/"
    },
    {
     "text": "JNJ Johnson & Johnson NYSE $266.93 +0.23%",
     "url": "https://clearank.com/stock/johnson-johnson-jnj/"
    },
    {
     "text": "ISRG Intuitive Surgical Inc. NASDAQ $377.16 -0.21%",
     "url": "https://clearank.com/stock/intuitive-surgical-isrg/"
    },
    {
     "text": "CRSP CRISPR Therapeutics AG NASDAQ $51.83 -2.13%",
     "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
    },
    {
     "text": "MOH Molina Healthcare Inc. NYSE $206.99 -3.31%",
     "url": "https://clearank.com/stock/moh-stock-analysis/"
    },
    {
     "text": "MCK McKesson Corporation NYSE $899.56 -1.25%",
     "url": "https://clearank.com/stock/mck-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "GOOGL vs GOOG Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/googl-vs-goog/"
    },
    {
     "text": "SCHD vs FDVV Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/schd-vs-fdvv/"
    },
    {
     "text": "XAU/USD vs SPY Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/gold-vs-sp500/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "DXCM Insider Trading Analysis",
   "facts": {
    "Bought": "$1.0M",
    "Sold": "$14.8M",
    "Insiders": "18",
    "Avg Transaction": "$438.5K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in DXCM",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Jan 13, 2021",
       "cells": [
        "SAYER KEVIN R Chief Executive Officer",
        "Sell",
        "47.0K",
        "$17.0M"
       ]
      },
      {
       "label": "Sep 15, 2020",
       "cells": [
        "ALTMAN STEVEN R Director",
        "Sell",
        "30.0K",
        "$11.8M"
       ]
      },
      {
       "label": "Mar 12, 2024",
       "cells": [
        "SAYER KEVIN R Chief Executive Officer",
        "Sell",
        "81.0K",
        "$10.8M"
       ]
      },
      {
       "label": "Sep 10, 2021",
       "cells": [
        "BLACKFORD QUENTIN S Chief Operating Officer",
        "Sell",
        "18.7K",
        "$10.2M"
       ]
      },
      {
       "label": "Sep 10, 2020",
       "cells": [
        "BLACKFORD QUENTIN S Chief Operating Officer",
        "Sell",
        "25.1K",
        "$10.0M"
       ]
      },
      {
       "label": "Jan 18, 2022",
       "cells": [
        "SAYER KEVIN R Chief Executive Officer",
        "Sell",
        "22.7K",
        "$9.9M"
       ]
      },
      {
       "label": "Jun 9, 2021",
       "cells": [
        "LEACH JACOB STEVEN Chief Technology Officer",
        "Sell",
        "22.8K",
        "$9.0M"
       ]
      },
      {
       "label": "Jun 22, 2021",
       "cells": [
        "SKYLER JAY S Director",
        "Sell",
        "20.0K",
        "$8.5M"
       ]
      },
      {
       "label": "Jun 11, 2020",
       "cells": [
        "LEACH JACOB STEVEN Chief Technology Officer",
        "Sell",
        "19.1K",
        "$7.2M"
       ]
      },
      {
       "label": "Apr 8, 2024",
       "cells": [
        "SAYER KEVIN R Chief Executive Officer",
        "Sell",
        "49.6K",
        "$6.9M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=DexCom+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "Is DexCom Inc. (DXCM) stock a buy right now?",
   "answer": "DexCom Inc. (DXCM) is currently rated a Buy with a consensus score of 75. The stock is trading at $86.45, with a median analyst price target of $94.00, suggesting an 8.7% upside. Consistent earnings beats and strong revenue growth support a positive outlook."
  },
  {
   "question": "What is DXCM's stock price forecast for 2030?",
   "answer": "Based on a Monte Carlo simulation, DexCom Inc. (DXCM) has a base case forecast of $128.82 for 2030, with a downside projection of $35.88 and an upside projection of $462.58. These figures represent statistical outcomes and not definitive price targets."
  },
  {
   "question": "How does DexCom Inc. compare to its sector peers?",
   "answer": "DexCom Inc. (DXCM) operates in the Healthcare sector with a P/E ratio of 34.17 and a P/S ratio of 6.57, both above the sector medians of 31.9 and 3.7 respectively. However, its return on equity (38.49%) and profit margin (20.12%) significantly outperform sector averages."
  },
  {
   "question": "What are the key catalysts for DexCom Inc. (DXCM)?",
   "answer": "Key catalysts include continued innovation in continuous glucose monitoring technology, potential expansion into new markets, and positive clinical trial results. Strong analyst conviction and consistent earnings beats also serve as positive catalysts for the stock."
  },
  {
   "question": "What are the main risks facing DexCom Inc. (DXCM)?",
   "answer": "The primary risks include its premium valuation, particularly its high price-to-sales ratio, and moderate insider selling. Increased competition in the medical device sector and potential regulatory hurdles are also factors to consider."
  },
  {
   "question": "How has DexCom Inc. performed in recent earnings reports?",
   "answer": "DexCom Inc. (DXCM) has consistently beaten earnings estimates, most recently reporting a 14.75% EPS surprise for the quarter to June 2026. This pattern of positive surprises indicates strong operational performance and demand for its products."
  },
  {
   "question": "What is the outlook for DexCom Inc. (DXCM) over the next 12 months?",
   "answer": "The outlook for DexCom Inc. (DXCM) is positive, supported by a Buy consensus rating and a median analyst price target of $94.00. Continued revenue growth projected at 10-12% for the current year and strong forward-looking estimates suggest potential for further appreciation."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "ILMN",
    "name": "Illumina Inc. NASDAQ",
    "price": "$222.36",
    "change": "+6.80%",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "BMY",
    "name": "Bristol-Myers Squibb Company NYSE",
    "price": "$63.73",
    "change": "-0.58%",
    "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/"
   },
   {
    "ticker": "CAPR",
    "name": "Capricor Therapeutics, Inc. NASDAQ",
    "price": "$8.56",
    "change": "-2.84%",
    "url": "https://clearank.com/stock/capr-stock-analysis/"
   },
   {
    "ticker": "JNJ",
    "name": "Johnson & Johnson NYSE",
    "price": "$266.93",
    "change": "+0.23%",
    "url": "https://clearank.com/stock/johnson-johnson-jnj/"
   },
   {
    "ticker": "ISRG",
    "name": "Intuitive Surgical Inc. NASDAQ",
    "price": "$377.16",
    "change": "-0.21%",
    "url": "https://clearank.com/stock/intuitive-surgical-isrg/"
   },
   {
    "ticker": "CRSP",
    "name": "CRISPR Therapeutics AG NASDAQ",
    "price": "$51.83",
    "change": "-2.13%",
    "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
   },
   {
    "ticker": "MOH",
    "name": "Molina Healthcare Inc. NYSE",
    "price": "$206.99",
    "change": "-3.31%",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   },
   {
    "ticker": "MCK",
    "name": "McKesson Corporation NYSE",
    "price": "$899.56",
    "change": "-1.25%",
    "url": "https://clearank.com/stock/mck-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "GOOGL vs GOOG Comparison",
    "name": "",
    "url": "https://clearank.com/compare/googl-vs-goog/"
   },
   {
    "ticker": "SCHD vs FDVV Comparison",
    "name": "",
    "url": "https://clearank.com/compare/schd-vs-fdvv/"
   },
   {
    "ticker": "XAU/USD vs SPY Comparison",
    "name": "",
    "url": "https://clearank.com/compare/gold-vs-sp500/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "SLVR",
    "text": "Sprott Silver Miners & Physical Silver ETF",
    "url": "https://clearank.com/etf/slvr-etf-analysis/"
   },
   {
    "ticker": "NTES",
    "text": "NetEase, Inc.",
    "url": "https://clearank.com/stock/ntes-stock-analysis/"
   },
   {
    "ticker": "PCAR",
    "text": "PACCAR Inc.",
    "url": "https://clearank.com/stock/pcar-stock-analysis/"
   },
   {
    "ticker": "O",
    "text": "Realty Income Corp.",
    "url": "https://clearank.com/stock/o-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "EGLD/USD",
    "text": "↓ 9.14%",
    "url": "https://clearank.com/crypto/egld-usd-crypto-analysis/"
   },
   {
    "ticker": "ARB/USD",
    "text": "↑ 19.42%",
    "url": "https://clearank.com/crypto/arbitrum-arb-usd/"
   },
   {
    "ticker": "WING",
    "text": "↓ 12.09%",
    "url": "https://clearank.com/stock/wingstop-wing/"
   },
   {
    "ticker": "INJ/USD",
    "text": "↓ 11.80%",
    "url": "https://clearank.com/crypto/injective-inj/"
   },
   {
    "ticker": "CRV/USD",
    "text": "↓ 11.53%",
    "url": "https://clearank.com/crypto/crv-usd-crypto-analysis/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "ABT",
    "text": "Abbott Laboratories",
    "url": "https://clearank.com/stock/abbott-laboratories-abt/"
   },
   {
    "ticker": "BSX",
    "text": "Boston Scientific Corporation",
    "url": "https://clearank.com/stock/boston-scientific-bsx/"
   },
   {
    "ticker": "EW",
    "text": "Edwards Lifesciences Corporation",
    "url": "https://clearank.com/stock/ew-stock-analysis/"
   },
   {
    "ticker": "GEHC",
    "text": "GE HealthCare",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   },
   {
    "ticker": "MDT",
    "text": "Medtronic plc",
    "url": "https://clearank.com/stock/medtronic-mdt/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/DXCM-dexcom-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/DXCM-dexcom-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "DexCom (DXCM) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/dxcm-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/dxcm-stock-analysis/",
        "name": "DexCom (DXCM) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/dxcm-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/dxcm-stock-analysis/",
     "name": "DexCom (DXCM) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-22T09:46:40+00:00",
     "dateModified": "2026-09-16T09:10:55+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/DXCM-dexcom-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/dxcm-stock-analysis/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/dxcm-stock-analysis/#richSnippet",
     "headline": "DexCom (DXCM) Stock Forecast & Price Target (2026)",
     "name": "DexCom (DXCM) Stock Forecast & Price Target (2026)",
     "description": "DexCom Inc. (DXCM) stock: Healthcare, Medical Devices. $32.6B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-22T09:46:40+00:00",
     "dateModified": "2026-09-16T09:10:55+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "DexCom Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "DXCM"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NASDAQ"
       }
      ],
      "description": "DexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health. Dexcom develops wearable biosensors, transmitters, receivers, and software that provide real-time glucose readings, trend data, and alerts to help users and clinicians monitor ",
      "tickerSymbol": "DXCM",
      "sameAs": "https://www.dexcom.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/dxcm-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/DXCM-dexcom-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/dxcm-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Is DexCom Inc. (DXCM) stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "DexCom Inc. (DXCM) is currently rated a Buy with a consensus score of 75. The stock is trading at $86.45, with a median analyst price target of $94.00, suggesting an 8.7% upside. Consistent earnings beats and strong revenue growth support a positive outlook."
     }
    },
    {
     "@type": "Question",
     "name": "What is DXCM's stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on a Monte Carlo simulation, DexCom Inc. (DXCM) has a base case forecast of $128.82 for 2030, with a downside projection of $35.88 and an upside projection of $462.58. These figures represent statistical outcomes and not definitive price targets."
     }
    },
    {
     "@type": "Question",
     "name": "How does DexCom Inc. compare to its sector peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "DexCom Inc. (DXCM) operates in the Healthcare sector with a P/E ratio of 34.17 and a P/S ratio of 6.57, both above the sector medians of 31.9 and 3.7 respectively. However, its return on equity (38.49%) and profit margin (20.12%) significantly outperform sector averages."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key catalysts for DexCom Inc. (DXCM)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Key catalysts include continued innovation in continuous glucose monitoring technology, potential expansion into new markets, and positive clinical trial results. Strong analyst conviction and consistent earnings beats also serve as positive catalysts for the stock."
     }
    },
    {
     "@type": "Question",
     "name": "What are the main risks facing DexCom Inc. (DXCM)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The primary risks include its premium valuation, particularly its high price-to-sales ratio, and moderate insider selling. Increased competition in the medical device sector and potential regulatory hurdles are also factors to consider."
     }
    },
    {
     "@type": "Question",
     "name": "How has DexCom Inc. performed in recent earnings reports?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "DexCom Inc. (DXCM) has consistently beaten earnings estimates, most recently reporting a 14.75% EPS surprise for the quarter to June 2026. This pattern of positive surprises indicates strong operational performance and demand for its products."
     }
    },
    {
     "@type": "Question",
     "name": "What is the outlook for DexCom Inc. (DXCM) over the next 12 months?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The outlook for DexCom Inc. (DXCM) is positive, supported by a Buy consensus rating and a median analyst price target of $94.00. Continued revenue growth projected at 10-12% for the current year and strong forward-looking estimates suggest potential for further appreciation."
     }
    }
   ]
  }
 ]
}